Neogen Corp. Stock
€4.10
Your prediction
Neogen Corp. Stock
Pros and Cons of Neogen Corp. in the next few years
Pros
Cons
Performance of Neogen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Neogen Corp. | -1.910% | -13.992% | -21.869% | -73.032% | -65.167% | - | - |
| Bio-Rad Labs Inc. A | 1.110% | 2.938% | 4.897% | -21.016% | -34.193% | -57.054% | -47.000% |
| Haemonetics Corp. | - | 5.085% | 7.826% | -19.481% | -17.881% | 5.085% | -17.881% |
| Merit Medical Systems | -0.630% | -0.625% | -4.217% | 3.922% | -13.115% | 57.426% | 110.317% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.NEOGEN CORP's current financial position shows significant challenges. Key findings include: - Revenue decline from $228.8 million to $221.0 million (year-over-year) - Net loss of $10.957 million compared to a loss of $2.022 million in the previous year - Significant asset impairment charges of $470.832 million - Cash balance decreased from $170.6 million to $127.7 million
The overall financial trend is negative, driven by declining revenue, increasing losses, and significant impairment charges.
These factors highlight both the challenges the company faces in terms of profitability and growth, as well as potential areas for improvement in financial management.
Comments
News
The Top-Ranked Insider Buys From April by Market Cap
Insiders are buying stock in 2025, and activity is not limited to a single sector or market cap. This article looks at the top three insider buys from April based on market cap and the number of
